SI
SI
discoversearch

 Biotech / Medical | Ribapharm Inc. - RNA


Previous 10 | Next 10 
To: D. K. G. who started this subject5/23/2003 1:56:09 PM
From: REH
   of 60
 
Serious buyers in this stock:

yahoo.multexinvestor.com 

REH/long

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: REH who wrote (49)5/28/2003 1:53:01 PM
From: Don Green
   of 60
 
REH

I see you are up to your old tricks again, posting under multiple Yahoo handles. Why do you continue to attempt to deceive?

cayflonor
messages.yahoo.com 

Heggenhougen
messages.yahoo.com 

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: Don Green who wrote (50)5/28/2003 9:20:29 PM
From: REH
   of 60
 
I believe RNA is a great buy at this price. Any factual comments received with thanks. bashers ignored.

REH

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)


To: REH who wrote (51)5/28/2003 10:32:02 PM
From: Don Green
   of 60
 
REH> Any factual comments received with thanks.

Nothing but the facts here!

REH
I see you are up to your old tricks again, posting under multiple Yahoo handles. Why do you continue to attempt to deceive?

cayflonor
messages.yahoo.com 

Heggenhougen
messages.yahoo.com 

Share Recommend | Keep | Reply | Mark as Last Read

To: REH who wrote (51)5/29/2003 12:50:18 PM
From: Don Green
   of 60
 
REH

What is the source for your rumor hyping on Yahoo?

RNA VS ICN, Should RNA be tracking
by: cayflonor
Long-Term Sentiment: Strong Buy 05/28/03 09:18 pm
Msg: 1430 of 1431


The rumors of ICN buying back RNA at $ 7.50 - $ 10.00 are still buzzing.
???? A total lack of ethics!

It seems you are just starting to believe your own hype!

Share Recommend | Keep | Reply | Mark as Last Read

To: D. K. G. who started this subject5/30/2003 9:51:05 AM
From: REH
   of 60
 
Volume on the buy side - technicals looking strong.

REH

Share Recommend | Keep | Reply | Mark as Last Read


To: D. K. G. who started this subject6/2/2003 8:44:58 AM
From: REH
   of 60
 
ICN Pharmaceuticals to Tender for Outstanding Shares of Ribapharm
COSTA MESA, Calif., June 2 /PRNewswire-FirstCall/ -- ICN Pharmaceuticals, Inc. (NYSE: ICN), today announced that it intends to make a tender offer for all of the outstanding shares of its subsidiary, Ribapharm Inc. (NYSE: RNA) that it does not already own. ICN currently owns approximately 80.1% of the outstanding common stock of Ribapharm and intends to offer to acquire the balance of Ribapharm common stock at a price of $5.60 per share in cash, representing a 20.2 percent premium over the one month average closing price of $4.66. The aggregate consideration payable under the offer for all of the outstanding Ribapharm shares would be approximately $168 million.

"We have conducted a comprehensive assessment of the best course of action with respect to our investment in Ribapharm, including an analysis of Ribapharm's value and the uncertainties and challenges that we believe are likely to remain with Ribapharm for sometime," said ICN Chairman and Chief Executive Officer Robert W. O'Leary. "We have concluded that now is an appropriate time to re-integrate Ribapharm, and we believe that this offer will provide stability to Ribapharm and its critical scientists, eliminate distractions, and better enable us to focus our efforts on augmenting our growing specialty pharmaceutical business."

ICN expects to file offering materials with the Securities and Exchange Commission and commence the tender offer within seven to ten days. At that time, offering materials will be mailed to Ribapharm stockholders. The commencement and completion of the tender offer does not require approval of the Ribapharm board of directors. Under applicable law, however, Ribapharm is required to file with the SEC a statement as to its position on the offer as well as other information within 10 business days of the date on which the offer is commenced.

The tender offer will be conditioned upon, among other things, the tender of a majority of Ribapharm shares not held by ICN or its affiliates, and ICN's ownership of at least 90% of the Ribapharm common stock on a fully diluted basis. The tender offer will not be conditioned on ICN obtaining any financing.

Following successful completion of the tender offer, ICN intends to effect a "short-form" merger, in which any shares not acquired by ICN in the tender offer would be acquired at the same $5.60 per share cash price paid in the tender offer.

Ribapharm stockholders and other interested parties are urged to read ICN's tender offer statement and other relevant documents filed with the SEC when they become available because they will contain important information. Ribapharm stockholders will be able to receive such documents free of charge at the SEC's web site, www.sec.gov, or from ICN at 3300 Hyland Avenue, Costa Mesa, CA 92626, Attn: Investor Relations.

ICN is an innovative, research-based global pharmaceutical company that manufactures, markets and distributes a broad range of prescription and non-prescription pharmaceuticals under the ICN brand name. Its research and new product development focuses on innovative treatments for dermatology, infectious diseases and cancer.

Share Recommend | Keep | Reply | Mark as Last Read

To: D. K. G. who started this subject6/2/2003 11:44:11 AM
From: Don Green
   of 60
 
Congrats on an impressive move higher today.

Don

Share Recommend | Keep | Reply | Mark as Last Read

To: D. K. G. who started this subject6/2/2003 4:38:30 PM
From: REH
   of 60
 
Good time to take the money and go elsewhere

REH/out

Suggest: RNR

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: REH who wrote (57)6/2/2003 6:09:59 PM
From: Don Green
   of 60
 
ICN tender for RNA
by: cayflonor

Long-Term Sentiment: Strong Buy 06/02/03 08:46 am
Msg: 1436 of 1443 messages.yahoo.com 

REH Jun 2, 2003 4:38 PM also (cayflonor on yahoo)

Good time to take the money and go elsewhere

REH/out


LOL! This man has no ethics!

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.